Contains Nonbinding Recommendations
Draft – Not for Implementation

Draft Guidance on Niraparib Tosylate
February 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Niraparib tosylate
Dosage Form: Tablet
Route: Oral
Strengths: EQ 100 mg Base, EQ 200 mg Base, EQ 300 mg Base

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Steady-state
   Design: Multiple-dose, two-treatment, two-period crossover
   Strength: Either EQ 200 mg Base only or EQ 300 mg Base only
   Subjects: Female patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy or female patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
   Additional comments: Exclude patients who require dosage modification or with expected changes in concomitant medications that may potentially affect the pharmacokinetics of niraparib during the study. Females of reproductive potential should use effective contraception during treatment and 6 months after the last dose of niraparib. Implement safety precautions and monitoring including complete blood count during treatment as recommended in the labeling. Niraparib can be administered with or without food per the labeling. For the purpose of a bioequivalence study, patients should be instructed to take the drug under similar food conditions during both periods of the study. Submission of an investigational new drug application is required prior to the conduct of a bioequivalence study for a cytotoxic drug of niraparib pursuant to 21 CFR § 320.31.
**Analyte to measure:** Niraparib in plasma

**Bioequivalence based on (90% CI):** Niraparib

**Waiver request of in vivo testing:** EQ 100 mg Base and EQ 200 mg Base strengths based on (i) acceptable bioequivalence study on the EQ 300 mg Base strength, (ii) acceptable in vitro dissolution testing across all the strengths, and (iii) proportional similarity of the formulations across all the strengths

Alternatively, EQ 100 mg Base and EQ 300 mg Base strengths based on (i) acceptable bioequivalence study on the EQ 200 mg Base strength, (ii) acceptable in vitro dissolution testing across all the strengths, and (iii) proportional similarity of the formulations across all the strengths

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

---

**Document History:** Recommended February 2024

**Unique Agency Identifier:** PSG_214876